George Souroullas, PhD

Medical School Department Internal Medicine
Research Program Solid Tumor Therapeutics
George Souroullas

Researcher Background

Primary Academic Title

Assistant Professor of Medicine, Division of Oncology, Section of Molecular Oncology, WashU Medicine

Training

  • 2011 - 2016: Postdoctoral, Cancer Genetics, University of North Carolina, Chapel Hill, NC

Education

  • 2010: PhD, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

Research & Selected Publications

Research Interest

Role of chromatin dynamics during cancer development, with a focus on B cell lymphomas and melanoma

Research Publications

ARID1A and ARID1B preserve B cell identity, prevent myeloid transformation and reveal therapeutic vulnerabilities.
Authors:

Lin PN, Park J, Kang YA, Souroullas GP

Journal & Year:

bioRxiv • 2025

Arid2 promotes Follicular B-cell differentiation and antibody responses in vivo.
Authors:

Paolini RL, Zimmerman S, Marjai S, one or more additional authors omitted Souroullas GP

Journal & Year:

bioRxiv • 2025

Developmental stage and cellular context determine oncogenic and molecular outcomes of Ezh2 Y641F mutation in hematopoiesis.
Authors:

Zimmerman SM, Procasky SJ, Smith SR, one or more additional authors omitted Souroullas GP

Journal & Year:

Blood Neoplasia • 2025

Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer.
Authors:

Fowle-Grider R, Rowles JL, Shen I, one or more additional authors omitted Souroullas GP, one or more additional authors omitted Patti GJ

Journal & Year:

Nature • 2024

Developmental Stage and Cellular Context Determine Oncogenic and Molecular Outcomes of Ezh2 Y641F Mutation in Hematopoiesis.
Authors:

Zimmerman SM, Procasky SJ, Smith SR, one or more additional authors omitted Souroullas GP

Journal & Year:

bioRxiv • 2024

Stat3-mediated Atg7 expression regulates anti-tumor immunity in mouse melanoma.
Authors:

Zimmerman SM, Suh E, Smith SR, Souroullas GP

Journal & Year:

Cancer Immunol Immunother • 2024

Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma.
Authors:

Zimmerman SM, Suh E, Smith SR, Souroullas GP

Journal & Year:

bioRxiv • 2024

The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance.
Authors:

Paolini RL, Souroullas GP

Journal & Year:

Cancer Discov • 2024